Loading
Glumetinib is a Chinese MET inhibitor approved in 2023 for lung cancers with MET exon 14 skipping, one of three such drugs approved in China and now in a phase 3 trial in gastric cancer.
Haihe Biopharma's glumetinib (SCC244) was approved by the NMPA in 2023 for locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping, on the GLORY phase 2 trial. It joins savolitinib and vebreltinib as China's approved MET inhibitors, alongside capmatinib and tepotinib elsewhere. A phase 3 trial in MET-amplified gastric cancer with chemotherapy is registered.
A highly selective type I MET kinase inhibitor for tumours driven by MET exon 14 skipping or amplification. Connects to MET.
1.Glumetinib slips into a pocket on MET.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2023 | Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Glumetinib" OR ABSTRACT:"Glumetinib" OR TITLE:"SCC244" OR ABSTRACT:"SCC244" OR TITLE:"Gumarontinib" OR ABSTRACT:"Gumarontinib" OR TITLE:"Haiyitan" OR ABSTRACT:"Haiyitan") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Glumetinib, not a curated reading list.
Shares Haihe Biopharma and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares Haihe Biopharma and the tag pipeline.
Shares Haihe Biopharma and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.